Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity

The aim of the study was to study the effect of albumin on the indicators of systemic inflammation and endothelial dysfunction in patients with ACL in combination with obesity. Material and Methods. The study included 52 patients with ACL in combination with obesity (confirmed before the onset of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N.H. Virstiuk, N.R. Matkovska
Formato:	article
Lenguaje:	EN UK
Publicado:	Danylo Halytsky Lviv National Medical University 2020
Materias:	alcoholic liver disease; liver cirrhosis; obesity; inflammation; endothelial dysfunction Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/6ff5baac17fe4e2db746445691841b79
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ff5baac17fe4e2db746445691841b79
record_format	dspace
spelling	oai:doaj.org-article:6ff5baac17fe4e2db746445691841b792021-11-10T19:49:51ZEffect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity1029-42442415-330310.25040/aml2020.02-03.055https://doaj.org/article/6ff5baac17fe4e2db746445691841b792020-09-01T00:00:00Zhttps://amljournal.com/index.php/journal/article/view/25https://doaj.org/toc/1029-4244https://doaj.org/toc/2415-3303The aim of the study was to study the effect of albumin on the indicators of systemic inflammation and endothelial dysfunction in patients with ACL in combination with obesity. Material and Methods. The study included 52 patients with ACL in combination with obesity (confirmed before the onset of ascites) with the first-onset uncomplicated ascites of grade 2-3, 46 men and 6 women aged 35 to 59 years; 32 patients were diagnosed with Child-Pugh score of class B, and 20 with Child-Pugh score of class C. Depending on the treatment, the patients were divided into 2 groups: Group I included 26 patients who received albumin 40.0 g/week in combination therapy for 2 weeks of inpatient treatment, and 20.0 g/week for 12 weeks of outpatient treatment, followed by a maintenance dose of 20.0 g/month (10.0 g/2 weeks) for 12 weeks; Group II included 26 patients who received basic therapy without albumin. The control group was comprised of 20 virtually healthy donors. The patients' condition, indicators of systemic inflammation and endothelial dysfunction were assessed before treatment, 12 and 24 weeks after the treatment onset. Results and Discussion. Within 24 weeks, all patients in both groups remained alive. In obese patients with ACL, the inclusion in the complex therapy of long-term use of albumin helps to improve the course of the disease according to the Child-Pugh score. The use of albumin in the complex treatment of patients with ACL in combination with obesity during 12 weeks helps to reduce the systemic inflammatory process in terms of hs-CRP and TNFa and to reduce endothelial dysfunction in terms of ADMA and IAP-1. The use of maintenance albumin therapy helps to stabilize the process with a tendency for further reduction of the indicators of CRP, TNFa, ADMA and IAP-1. Increased systemic inflammation and endothelial dysfunction are reported in patients who did not receive long-term albumin therapy. Conclusions. The use of albumin at a dose of 20.0 g/week during 12 weeks of outpatient treatment helps to improve the course of ALC in combination with obesity according to the Child-Pugh score, along with a decrease in systemic inflammation and endothelial dysfunction. The use of maintenance therapy with albumin of 20.0 g/month during 12 weeks helps to stabilize the patient's condition with a tendency to further reduction of the incidence of systemic inflammation and endothelial dysfunction.N.H. VirstiukN.R. MatkovskaDanylo Halytsky Lviv National Medical Universityarticlealcoholic liver disease; liver cirrhosis; obesity; inflammation; endothelial dysfunctionMedicine (General)R5-920ENUKActa Medica Leopoliensia, Vol 26, Iss 2-3, Pp 55-60 (2020)
institution	DOAJ
collection	DOAJ
language	EN UK
topic	alcoholic liver disease; liver cirrhosis; obesity; inflammation; endothelial dysfunction Medicine (General) R5-920
spellingShingle	alcoholic liver disease; liver cirrhosis; obesity; inflammation; endothelial dysfunction Medicine (General) R5-920 N.H. Virstiuk N.R. Matkovska Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
description	The aim of the study was to study the effect of albumin on the indicators of systemic inflammation and endothelial dysfunction in patients with ACL in combination with obesity. Material and Methods. The study included 52 patients with ACL in combination with obesity (confirmed before the onset of ascites) with the first-onset uncomplicated ascites of grade 2-3, 46 men and 6 women aged 35 to 59 years; 32 patients were diagnosed with Child-Pugh score of class B, and 20 with Child-Pugh score of class C. Depending on the treatment, the patients were divided into 2 groups: Group I included 26 patients who received albumin 40.0 g/week in combination therapy for 2 weeks of inpatient treatment, and 20.0 g/week for 12 weeks of outpatient treatment, followed by a maintenance dose of 20.0 g/month (10.0 g/2 weeks) for 12 weeks; Group II included 26 patients who received basic therapy without albumin. The control group was comprised of 20 virtually healthy donors. The patients' condition, indicators of systemic inflammation and endothelial dysfunction were assessed before treatment, 12 and 24 weeks after the treatment onset. Results and Discussion. Within 24 weeks, all patients in both groups remained alive. In obese patients with ACL, the inclusion in the complex therapy of long-term use of albumin helps to improve the course of the disease according to the Child-Pugh score. The use of albumin in the complex treatment of patients with ACL in combination with obesity during 12 weeks helps to reduce the systemic inflammatory process in terms of hs-CRP and TNFa and to reduce endothelial dysfunction in terms of ADMA and IAP-1. The use of maintenance albumin therapy helps to stabilize the process with a tendency for further reduction of the indicators of CRP, TNFa, ADMA and IAP-1. Increased systemic inflammation and endothelial dysfunction are reported in patients who did not receive long-term albumin therapy. Conclusions. The use of albumin at a dose of 20.0 g/week during 12 weeks of outpatient treatment helps to improve the course of ALC in combination with obesity according to the Child-Pugh score, along with a decrease in systemic inflammation and endothelial dysfunction. The use of maintenance therapy with albumin of 20.0 g/month during 12 weeks helps to stabilize the patient's condition with a tendency to further reduction of the incidence of systemic inflammation and endothelial dysfunction.
format	article
author	N.H. Virstiuk N.R. Matkovska
author_facet	N.H. Virstiuk N.R. Matkovska
author_sort	N.H. Virstiuk
title	Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
title_short	Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
title_full	Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
title_fullStr	Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
title_full_unstemmed	Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
title_sort	effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity
publisher	Danylo Halytsky Lviv National Medical University
publishDate	2020
url	https://doaj.org/article/6ff5baac17fe4e2db746445691841b79
work_keys_str_mv	AT nhvirstiuk effectofalbuminonindicatorsofsystemicinflammationandendothelialdysfunctioninpatientswithalcoholiclivercirrhosisincombinationwithobesity AT nrmatkovska effectofalbuminonindicatorsofsystemicinflammationandendothelialdysfunctioninpatientswithalcoholiclivercirrhosisincombinationwithobesity
_version_	1718439786053632000

Effect of albumin on indicators of systemic inflammation and endothelial dysfunction in patients with alcoholic liver cirrhosis in combination with obesity

Ejemplares similares